Prostaglandin_NN
E2_NN
induction_NN
of_IN
binding_NN
activity_NN
to_TO
CRE_NN
and_CC
AP-2_NN
elements_NNS
in_IN
human_JJ
T_NN
lymphocytes_NNS
._.

Prostaglandins_NNP
of_IN
the_DT
E_NN
series_NN
are_VBP
immunomodulatory_JJ
agents_NNS
which_WDT
exert_VBP
inhibitory_JJ
as_RB
well_RB
as_IN
stimulatory_JJ
effects_NNS
on_IN
a_DT
variety_NN
of_IN
immune_JJ
responses_NNS
._.

Since_IN
it_PRP
is_VBZ
known_VBN
that_IN
PGE2_NN
is_VBZ
able_JJ
to_TO
increase_VB
cAMP_NN
levels_NNS
,_,
we_PRP
investigated_VBD
whether_IN
it_PRP
can_MD
affect_VB
gene_NN
expression_NN
through_IN
the_DT
activation_NN
of_IN
the_DT
transcription_NN
factors_NNS
which_WDT
bind_VBP
enhancer_NN
elements_NNS
in_IN
the_DT
promoter_NN
regions_NNS
of_IN
cAMP-regulated_JJ
genes_NNS
._.

Using_VBG
electrophoretic_JJ
mobility_NN
shift_NN
assay_NN
,_,
we_PRP
demonstrated_VBD
that_IN
a_DT
short_JJ
treatment_NN
of_IN
human_JJ
T_NN
lymphocytes_NNS
with_IN
PGE2_NN
induces_VBZ
specific_JJ
binding_NN
activity_NN
to_TO
CRE_NN
and_CC
AP-2_NN
,_,
but_CC
not_RB
AP-1_NN
,_,
DNA_NN
elements_NNS
._.

Since_IN
the_DT
okadaic_JJ
acid_NN
,_,
a_DT
potent_JJ
protein_NN
phosphatase_NN
inhibitor_NN
,_,
prolongs_VBZ
the_DT
induction_NN
of_IN
the_DT
binding_NN
activity_NN
,_,
phosphorylation_NN
events_NNS
are_VBP
likely_JJ
to_TO
occur_VB
._.

This_DT
activity_NN
seems_VBZ
to_TO
be_VB
due_JJ
to_TO
increased_VBN
cAMP_NN
levels_NNS
because_IN
forskolin_NN
and_CC
IBMX_NN
mimic_VBP
the_DT
effects_NNS
of_IN
PGE2_NN
._.

More_RBR
interestingly_RB
,_,
transfection_NN
experiments_NNS
with_IN
CRE-CAT_NN
plasmide_NN
show_VBP
that_IN
PGE2_NN
activates_VBZ
the_DT
transcription_NN
of_IN
a_DT
CRE-containing_NN
promoter_NN
._.

These_DT
data_NNS
support_VBP
the_DT
positive_JJ
role_NN
for_IN
PGE2_NN
on_IN
some_DT
immune_JJ
functions_NNS
._.

